Open Label, Two Cohort (With and Without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients With Gaucher Disease Type 1 and Type 3

Trial Profile

Open Label, Two Cohort (With and Without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients With Gaucher Disease Type 1 and Type 3

Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2018

At a glance

  • Drugs Eliglustat (Primary) ; Imiglucerase (Primary)
  • Indications Gaucher's disease type I; Gaucher's disease type III
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms ELIKIDS
  • Sponsors Sanofi; Sanofi Genzyme
  • Most Recent Events

    • 13 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 04 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top